Non-Hodgkin Lymphoma Clinical Trials in Beijing, Beijing Municipality
7 recruitingBeijing, Beijing Municipality, China
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled75 locationsNCT05283720
Recruiting
Phase 1
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.110 enrolled13 locationsNCT06219356
Recruiting
Phase 1Phase 2
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled1 locationNCT06838832
Recruiting
Phase 1Phase 2
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled2 locationsNCT06321289